Schulze-Bergkamen Henning, Fleischer Binje, Schuchmann Marcus, Weber Achim, Weinmann Arndt, Krammer Peter H, Galle Peter R
First Department of Medicine, Johannes-Gutenberg-University Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany.
BMC Cancer. 2006 Oct 2;6:232. doi: 10.1186/1471-2407-6-232.
Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide and a major cause of cancer-related mortality. HCC is highly resistant to currently available chemotherapeutic drugs. Defects in apoptosis signaling contribute to this resistance. Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 protein family which interferes with mitochondrial activation. In a previous study we have shown that Mcl-1 is highly expressed in tissues of human HCC. In this study, we manipulated expression of the Mcl-1 protein in HCC cells by RNA interference and analyzed its impact on apoptosis sensitivity of HCC cells in vitro.
RNA interference was performed by transfecting siRNA to specifically knock down Mcl-1 expression in HCC cells. Mcl-1 expression was measured by quantitative real-time PCR and Western blot. Induction of apoptosis and caspase activity after treatment with chemotherapeutic drugs and different targeted therapies were measured by flow cytometry and fluorometric analysis, respectively.
Here we demonstrate that Mcl-1 expressing HCC cell lines show low sensitivity towards treatment with a panel of chemotherapeutic drugs. However, treatment with the anthracycline derivative epirubicin resulted in comparatively high apoptosis rates in HCC cells. Inhibition of the kinase PI3K significantly increased apoptosis induction by chemotherapy. RNA interference efficiently downregulated Mcl-1 expression in HCC cells. Mcl-1 downregulation sensitized HCC cells to different chemotherapeutic agents. Sensitization was accompanied by profound activation of caspase-3 and -9. In addition, Mcl-1 downregulation also increased apoptosis rates after treatment with PI3K inhibitors and, to a lower extent, after treatment with mTOR, Raf I and VEGF/PDGF kinase inhibitors. TRAIL-induced apoptosis did not markedly respond to Mcl-1 knockdown. Additionally, knockdown of Mcl-1 efficiently enhanced apoptosis sensitivity towards combined treatment modalities: Mcl-1 knockdown significantly augmented apoptosis sensitivity of HCC cells towards chemotherapy combined with PI3K inhibition.
Our data suggest that specific downregulation of Mcl-1 by RNA interference is a promising approach to sensitize HCC cells towards chemotherapy and molecularly targeted therapies.
肝细胞癌(HCC)是全球最常见的癌症之一,也是癌症相关死亡的主要原因。HCC对目前可用的化疗药物具有高度抗性。凋亡信号缺陷导致了这种抗性。髓样细胞白血病-1(Mcl-1)是Bcl-2蛋白家族的抗凋亡成员,它干扰线粒体激活。在先前的研究中,我们已经表明Mcl-1在人HCC组织中高表达。在本研究中,我们通过RNA干扰操纵HCC细胞中Mcl-1蛋白的表达,并分析其对HCC细胞体外凋亡敏感性的影响。
通过转染siRNA进行RNA干扰,以特异性敲低HCC细胞中Mcl-1的表达。通过定量实时PCR和蛋白质印迹法测量Mcl-1的表达。分别通过流式细胞术和荧光分析测量化疗药物和不同靶向治疗后凋亡的诱导和半胱天冬酶活性。
在这里,我们证明表达Mcl-1的HCC细胞系对一组化疗药物的治疗显示出低敏感性。然而,用蒽环类衍生物表柔比星治疗导致HCC细胞中相对较高的凋亡率。抑制激酶PI3K显著增加化疗诱导的凋亡。RNA干扰有效地下调了HCC细胞中Mcl-1的表达。Mcl-1的下调使HCC细胞对不同的化疗药物敏感。致敏伴随着caspase-3和-9的深度激活。此外,Mcl-1的下调还增加了用PI3K抑制剂治疗后的凋亡率,在用mTOR、Raf I和VEGF/PDGF激酶抑制剂治疗后,凋亡率有所降低。TRAIL诱导的凋亡对Mcl-1敲低没有明显反应。此外,Mcl-1的敲低有效地增强了对联合治疗方式的凋亡敏感性:Mcl-1敲低显著增强了HCC细胞对化疗联合PI3K抑制的凋亡敏感性。
我们的数据表明,通过RNA干扰特异性下调Mcl-1是使HCC细胞对化疗和分子靶向治疗敏感的一种有前景的方法。